{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:59:34Z","timestamp":1773323974726,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T00:00:00Z","timestamp":1400716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1208\/s12249-014-0133-8","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T20:01:37Z","timestamp":1400702497000},"page":"1070-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Challenges and Opportunities to Use Biowaivers to Compare Generics in China"],"prefix":"10.1208","volume":"15","author":[{"given":"Jieyu","family":"Zuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bou-Chacra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"133_CR1","unstructured":"World Health Organization. Country pharmaceutical situations: fact book on WHO level 1 indicators 2007. Geneva: WHO. 2009. http:\/\/apps.who.int\/medicinedocs\/documents\/s16874e\/s16874e.pdf Accessed 20 Nov 2012."},{"key":"133_CR2","unstructured":"World Health Organization. Essential medicines and health product. 2012. http:\/\/www.who.int\/medicines\/en\/ Accessed 20 Nov 2012."},{"key":"133_CR3","unstructured":"Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. 2000. www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070246.pdf . Accessed 20 Nov 2012."},{"key":"133_CR4","unstructured":"World Health Organization. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Annex 7 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: WHO Technical Report Series No.937, 2006; 40th report: p.347-90. http:\/\/apps.who.int\/prequal\/info_general\/documents\/TRS937\/WHO_TRS_937__annex7_eng.pdf Accessed 20 Nov 2012."},{"key":"133_CR5","unstructured":"World Health Organization. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines\u2014immediate-release, solid oral dosage forms. Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: WHO Technical Report Series No.937, 2006; 40th report: p.391-461. http:\/\/apps.who.int\/prequal\/info_general\/documents\/TRS937\/WHO_TRS_937__annex8_eng.pdf Accessed 20 Nov 2012."},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mcp.2002.126705","volume":"72","author":"RL Williams","year":"2002","unstructured":"Williams RL, Chen ML, Hauck WW. Equivalence approaches. Clin Pharmacol Ther. 2002;72:229\u201337. doi: 10.1067\/mcp.2002.126705 .","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR7","unstructured":"Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations, 33rd ed. Rockville: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Pharmaceutical Science Office of Generic Drugs. 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/UCM071436.pdf Accessed 20 Apr 2013."},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF03190051","volume":"25","author":"M Spino","year":"2000","unstructured":"Spino M, Tsang YC, Pop R. Dissolution and in vivo evidence of differences in reference products: impact on development of generic drugs. Eur J Drug Metab Pharmacokinet. 2000;25:18\u201324.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jval.2012.04.004","volume":"15","author":"A Cameron","year":"2012","unstructured":"Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15:664\u201373. doi: 10.1016\/j.jval.2012.04.004 .","journal-title":"Value Health"},{"key":"133_CR10","unstructured":"GBI research. China pharmaceutical market outlook\u2014government incentives, healthcare reform and a rapidly ageing population provide strong stimulus for growth. 2013. http:\/\/www.researchandmarkets.com\/research\/pgk2g8\/china Accessed 20 Apr 2013."},{"key":"133_CR11","unstructured":"Hirschler B. China seen as no. 2 drugs market by 2015. Reuters. 2010 Nov 8 http:\/\/uk.reuters.com\/article\/2010\/11\/08\/us-summit-china-drugs-idUKTRE6A73SL20101108 Accessed 8 May 2013."},{"key":"133_CR12","unstructured":"Deloitte China. The next phase: opportunities in China's pharmaceuticals market. 2012. http:\/\/www.deloitte.com\/view\/en_CN\/cn\/ind\/lshc\/723313bbb0943310VgnVCM3000001c56f00aRCRD.htm Accessed 20 Apr 2013."},{"key":"133_CR13","unstructured":"Vesiongain. Chinese pharmaceutical market 2013\u20132023. 2013. http:\/\/www.visiongain.com\/Report\/1018\/Chinese-Pharmaceutical-Market-2013-2023 Accessed 8 May 2013."},{"key":"133_CR14","unstructured":"China Food and Drug Administration. Regulation on drug registration (\u300a\u836f\u54c1\u6ce8\u518c\u7ba1\u7406\u529e\u6cd5\u300b) Order 28, 2007.Chinese. http:\/\/www.sfda.gov.cn\/WS01\/CL0053\/24529.html Accessed 21 Apr 2013."},{"key":"133_CR15","unstructured":"Database of pharmaceutical manufacturer (\u836f\u54c1\u751f\u4ea7\u4f01\u4e1a). China Food and Drug Administration, Beijing. 2013. Chinese. http:\/\/app1.sfda.gov.cn\/datasearch\/face3\/dir.html Accessed 21 Apr 2013."},{"key":"133_CR16","unstructured":"China Food and Drug Administration. Annual report of registration and approval of 2011(2011\u836f\u54c1\u6ce8\u518c\u5ba1\u6279\u5e74\u5ea6\u62a5\u544a). China Food and Drug Administration. 2012. Chinese. http:\/\/www.sda.gov.cn\/WS01\/CL0050\/75250.html Accessed 10 Feb 2013."},{"key":"133_CR17","unstructured":"Uniformity of dosage units <905>. In United States Pharmacopeia and National Formulary USP 36\u2013NF 31. Rockville: The United States Pharmacopeial Convention; 2013. p. 431\u20133."},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263\u201371. doi: 10.1208\/s12248-010-9185-1 .","journal-title":"AAPS J"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1208\/s12248-012-9350-9","volume":"14","author":"R L\u00f6benberg","year":"2012","unstructured":"L\u00f6benberg R, Chacra NB, Stippler ES, Shah VP, DeStefano AJ, Hauck WW, et al. Toward global standards for comparator pharmaceutical products: case studies of amoxicillin, metronidazole, and zidovudine in the Americas. AAPS J. 2012;14:462\u201372. doi: 10.1208\/s12248-012-9350-9 .","journal-title":"AAPS J"},{"key":"133_CR20","unstructured":"World Health Organization. Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products. Annex 11 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: WHO Technical Report Series No.902, 2002; 36th report: p.161-80. http:\/\/apps.who.int\/medicinedocs\/documents\/s19641en\/s19641en.pdf Accessed 20 Nov 2012."},{"key":"133_CR21","unstructured":"Database of imported drug product (\u8fdb\u53e3\u836f\u54c1). China Food and Drug Administration, Beijing. 2013. Chinese. http:\/\/app1.sfda.gov.cn\/datasearch\/face3\/dir.html Accessed 20 Nov 2012."},{"key":"133_CR22","unstructured":"Drug Product Database Online Query. Health Canada, Ottawa. 2012. http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/index-eng.jsp Accessed 20 Nov 2012."},{"key":"133_CR23","unstructured":"China Food and Drug Administration. Guideline of development of chemical generics with existing state standard (\u5df2\u6709\u56fd\u5bb6\u6807\u51c6\u5316\u5b66\u836f\u54c1\u7814\u7a76\u6280\u672f\u6307\u5bfc\u539f\u5219). China Food and Drug Administration. 2007. Chinese. http:\/\/www.cde.org.cn\/zdyz.do?method=largePage&id=2076 Accessed 1 May 2013."},{"key":"133_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1057\/jgm.2008.19","volume":"5","author":"RL Williams","year":"2008","unstructured":"Williams RL, Shah VP. Continuing equivalence: is there an end to the story? J Generic Med. 2008;5:297\u2013304.","journal-title":"J Generic Med"},{"key":"133_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.10.015","volume":"290","author":"Y Wu","year":"2005","unstructured":"Wu Y, Fassihi R. Stability of metronidazole, tetracycline HCl and famotidine alone and in combination. Int J Pharm. 2005;290:1\u201313. doi: 10.1016\/j.ijpharm.2004.10.015 .","journal-title":"Int J Pharm"},{"key":"133_CR26","unstructured":"Amoxicillin capsules (\u963f\u83ab\u897f\u6797\u80f6\u56ca). In Pharmacopoeia of the People's Republic of China 2010, vol. 2 (\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u836f\u51782010\u7248\u4e8c\u90e8). Beijing: Chinese Pharmacopeia Commission. p. 403\u20134. Chinese."},{"key":"133_CR27","unstructured":"Metronidazole tablets (\u7532\u785d\u5511\u7247). In Pharmacopoeia of the People's Republic of China 2010, vol.2 (\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u836f\u51782010\u7248\u4e8c\u90e8). Beijing: Chinese Pharmacopeia Commission. p. 153\u20134. Chinese."},{"key":"133_CR28","unstructured":"Database of domestic drug product (\u56fd\u4ea7\u836f\u54c1). China Food and Drug Administration, Beijing. 2013. Chinese. http:\/\/app1.sfda.gov.cn\/datasearch\/face3\/dir.html Accessed 21 Apr 2013."},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/4551168a","volume":"455","author":"D Cyranoski","year":"2008","unstructured":"Cyranoski D. Pharmaceutical futures: made in China? Nature. 2008;455:1168\u201370. doi: 10.1038\/4551168a .","journal-title":"Nature"},{"key":"133_CR30","unstructured":"China Food and Drug Administration. View of reforming the drug approval process to encourage drug innovation (Draft) (\u5173\u4e8e\u6df1\u5316\u836f\u54c1\u5ba1\u8bc4\u5ba1\u6279\u6539\u9769\u8fdb\u4e00\u6b65\u9f13\u52b1\u836f\u7269\u521b\u65b0\u7684\u610f\u89c1) (\u5f81\u6c42\u610f\u89c1\u7a3f). China Food and Drug Administration.2012. Chinese. http:\/\/www.sda.gov.cn\/WS01\/CL0778\/77409.html Accessed 1 May 2013."},{"key":"133_CR31","unstructured":"China Food and Drug Administration. Evaluation scheme of generic quality consistency(\u4eff\u5236\u836f\u8d28\u91cf\u4e00\u81f4\u6027\u8bc4\u4ef7\u5de5\u4f5c\u65b9\u6848). China Food and Drug Administration.2013. Chinese. http:\/\/www.sfda.gov.cn\/WS01\/CL0844\/78516.html Accessed 1 May 2013."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-014-0133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-014-0133-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-014-0133-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:48:27Z","timestamp":1559620107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-014-0133-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1208\/s12249-014-0133-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}